News

FDA approves Odactra to treat house dust mite (HDM)-induced allergic rhinitis

Read time: 1 mins

Published:1st Feb 2023

ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts

ODACTRA is approved for use in persons 12 through 65 years of age.

Condition: Allergic Rhinitis/Dust Mite

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Ojemda (tovorafenib) receives FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), the most common form of childhood brain tumor

Day One Biopharmaceuticals, Inc , announced that the FDA has approved Ojemda (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory BRAF-altered pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

4 mins

Drug news

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria.

Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety

3 min

Drug news

European Commission approves Emblaveo (aztreonam-avibactam) for patients with multidrug-resistant infections and limited treatment options

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Emblaveo (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis

1 min

See all news